Currently out of the existing stock ratings of Steven Breazzano, 5 are a HOLD (55.56%), 4 are a BUY (44.44%).

Steven Breazzano

Work Performance Price Targets & Ratings Chart

Analyst Steven Breazzano, carries an average stock price target met ratio of 100% that have a potential upside of 22.53% achieved within 119 days. Previously, Steven Breazzano worked at PIPER SANDLER.

Steven Breazzano’s has documented 19 price targets and ratings displayed on 3 stocks. The coverage was on the Healthcare sector.

Most recent stock forecast was given on RARE, Ultragenyx at 23-Mar-2017.

Wall Street Analyst Steven Breazzano

Analyst best performing recommendations are on MRTX (MIRATI THER).
The best stock recommendation documented was for MRTX (MIRATI THER) at 6/3/2016. The price target of $14 was fulfilled within 3 days with a profit of $4.35 (23.71%) receiving and performance score of 79.02.

Average potential price target upside

CLVS Clovis Oncology RARE Ultragenyx MRTX Mirati Ther

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Hold

$4

3 years 5 months 29 days ago
(14-Jun-2022)

0/11 (0%)

$2.53 (172.11%)

Hold

$4.75

$4.66 (5177.78%)

$5.75

4 years 1 months 10 days ago
(03-Nov-2021)

10/12 (83.33%)

$0.06 (1.28%)

65

Sell

5 years 1 months 7 days ago
(06-Nov-2020)

3/5 (60%)

$5.73 (134.19%)

42

Buy

$16

$15.91 (17677.78%)

$17

5 years 4 months 6 days ago
(07-Aug-2020)

5/12 (41.67%)

$10.58 (195.20%)

77

Sell

$4

$3.91 (4344.44%)

$3

5 years 7 months 7 days ago
(06-May-2020)

3/5 (60%)

$-4.07 (-50.43%)

191

Show more analysts

Please expand the browser size to see the chart

What Year was the first public recommendation made by Steven Breazzano?

On 2015

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?